Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Moazedi-Fuerst, FC; Kielhauser, SM; Hermann, J; Meilinger, M; Demel, U; Stradner, MH; Graninger, WB.
Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?
Scand J Rheumatol. 2015; 44(6):519-520
Doi: 10.3109/03009742.2015.1069888
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Moazedi-Fürst Florentine
- Co-Autor*innen der Med Uni Graz
-
Demel Ulrike
-
Graninger Winfried
-
Hermann Josef
-
Kielhauser Sonja
-
Meilinger Michael
-
Stradner Martin Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Find related publications in this database (using NLM MeSH Indexing)
-
Antibodies, Antinuclear - blood
-
Antibodies, Antinuclear - immunology
-
Antirheumatic Agents - therapeutic use
-
Autoantibodies - blood
-
Autoantibodies - immunology
-
Biomarkers - blood
-
DNA Topoisomerases, Type I - blood
-
DNA Topoisomerases, Type I - immunology
-
Dose-Response Relationship, Drug -
-
Humans -
-
Immunologic Surveillance -
-
Rituximab - therapeutic use
-
Scleroderma, Diffuse - blood
-
Scleroderma, Diffuse - drug therapy
-
Scleroderma, Diffuse - immunology
-
Sensitivity and Specificity -
-
Time Factors -
-
Treatment Outcome -